Skip Navigation


NDT Advance Access originally published online on May 26, 2005
Nephrology Dialysis Transplantation 2005 20(7):1518-1519; doi:10.1093/ndt/gfh908
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/7/1518    most recent
gfh908v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rose, M.
Right arrow Articles by Walker, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rose, M.
Right arrow Articles by Walker, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Letter

Renal failure following bowel cleansing with a sodium phosphate purgative

The first 10% of the full text of this article appears below.

Sir,

Visicol® Tablets (InKine Pharmaceutical Co., Inc.) have been used in >1.2 million patients as a bowel preparation for colonoscopy. To date, InKine Pharmaceuticals has received one report of nephrocalcinosis following use of Visicol®. This case was described by Markowitz et al. in the April 2005 issue of the journal along with 15 cases associated with the use of oral sodium phosphate solution (OSPS, Fleet® Phospho®-Soda, C.B. Fleet). Data . . . [Full Text of this Article]

Martin Rose, Robyn G. Karlstadt and Kelli Walker

InKine Pharmaceutical Co. Inc. Blue Bell PA 19422 USA Email: kwalker@inkine.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 QJMHome page
M.A.C. Onuigbo
Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection
QJM, March 1, 2009; 102(3): 155 - 167.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
E. Ritz
Nephrology Potpourri
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1253 - 1259.
[Full Text] [PDF]

Home page
 NEJMHome page
T. I. Steinman, A. E. Samir, and L. D. Cornell
Case 27-2008 -- A 64-Year-Old Man with Abdominal Pain, Nausea, and an Elevated Level of Serum Creatinine
N. Engl. J. Med., August 28, 2008; 359(9): 951 - 960.
[Full Text] [PDF]

Home page
 BMJHome page
A. Connor, L. Sykes, I. S D Roberts, and C. E Weston
Acute phosphate nephropathy after sodium phosphate preparations
BMJ, July 17, 2008; 337(jul17_1): a182 - a182.
[Full Text]

Home page
 Arch Intern MedHome page
A. Khurana, L. McLean, S. Atkinson, and C. J. Foulks
The Effect of Oral Sodium Phosphate Drug Products on Renal Function in Adults Undergoing Bowel Endoscopy
Arch Intern Med, March 24, 2008; 168(6): 593 - 597.
[Abstract] [Full Text] [PDF]